198 related articles for article (PubMed ID: 24902903)
1. Lhx2 regulates bone remodeling in mice by modulating RANKL signaling in osteoclasts.
Kim JH; Youn BU; Kim K; Moon JB; Lee J; Nam KI; Park YW; O'Leary DD; Kim KK; Kim N
Cell Death Differ; 2014 Oct; 21(10):1613-21. PubMed ID: 24902903
[TBL] [Abstract][Full Text] [Related]
2. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
3. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
4. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
5. MafB negatively regulates RANKL-mediated osteoclast differentiation.
Kim K; Kim JH; Lee J; Jin HM; Kook H; Kim KK; Lee SY; Kim N
Blood; 2007 Apr; 109(8):3253-9. PubMed ID: 17158225
[TBL] [Abstract][Full Text] [Related]
6. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
[TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
8. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
11. ATF3 modulates calcium signaling in osteoclast differentiation and activity by associating with c-Fos and NFATc1 proteins.
Jeong BC; Kim JH; Kim K; Kim I; Seong S; Kim N
Bone; 2017 Feb; 95():33-40. PubMed ID: 27829167
[TBL] [Abstract][Full Text] [Related]
12. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.
Han SY; Kim YK
Am J Chin Med; 2019; 47(2):439-455. PubMed ID: 30827151
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
14. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
15. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
[TBL] [Abstract][Full Text] [Related]
16. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
18. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
19. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
[TBL] [Abstract][Full Text] [Related]
20. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival.
Fujiwara T; Zhou J; Ye S; Zhao H
Cell Death Dis; 2016 Jul; 7(7):e2300. PubMed ID: 27441652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
